UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2024

ABSCI CORPORATION

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-40646 (Commission File Number)

85-3383487 (I.R.S. Employer Identification No.)

18105 SE Mill Plain Blvd Vancouver, WA 98683 (Address of principal executive offices, including zip code)

(360) 949-1041

(Registrant's telephone number, including area code)

Not Applicable (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Common Stock, \$0.0001 par value per share Trading Symbol(s) ABSI

Name of each exchange on which registered The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company \boxtimes

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events

On January 8, 2024, Absci Corporation (the "Company") announced that it will present a business update at the 42nd Annual J.P. Morgan Healthcare Conference. A copy of the slides from the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The presentation is available in the "Events and Presentations" section of the Company's investor relations website at investors.absci.com.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits	
Exhibit No.	Description
99.1	Slides from Absci Corporation's presentation filed on January 8, 2024.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Absci Corporation

Date: January 8, 2024

By: /s/ Sean McClain

Sean McClain Founder and CEO



Disclaimers

Forward-Looking Statements Certain statements in this presentation that are not historical facts are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words "will," "may," "anticipates," "plans," "believes," "forecast," "estimates," "expects," "predicts," "advancing," "aim," "potential," and "intends," or similar expressions. We intend these forward-looking statements, including statements regarding our strategy, estimated speed, cost advantages, improved success rates, and expanded intellectual property opportunities from developing therapeutics leveraging our Al drug creation platform, the effective incorporation of our technology development collaboration efforts, including growing partnership momentum for 2024, potential total dollar value of, and milestone and royalty payments due under, our collaboration afforts, including growing partnership momentum for 2024, potential total dollar value of, and milestone and royalty payments due under, our collaboration afforts, including growing partnership momentum for 2024, potential total dollar value of, and milestone and royalty payments due under, our collaboration agreements, projected costs, prospects, plans and objectives of management, to be covered by the safe harbor provisions for forward-looking statements contailed in Section 27A of the Securities Act and Section 21E of the Securities Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be atfacted by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncert

Market and Statistical Information This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other industry data. These di involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified the data generated by independent parties and cannot guarantee their accuracy or completeness. data

Trademark usage

Trademark usage
Trademark usage
This presentation/document/webpage contains references to our trademarks and service marks and to those belonging to third parties. Absciø, the Absci logo mark (a),
SoluProø, Bionic SoluProø, and SoluPureø are Absci registered trademarks with the U.S. Patent and Trademark Office. We also use various other trademarks, service marks and
trade names in our business, including the the Absci A logo mark (a), the Unlimit with the usark (amount), the unlimit symbol (unlimit -), Bionic protein ", Bionic Enzyme ", Bionic
Antibody", Denovium "Denovium Engine ", Drug Creation ", HiPrug Creatio

COPYRIGHTE 2024 ABSCI CORPORATION. | ALL RIGHTS RESERVED.

absci | 2



Our Integrated AI & Wet Lab Platform Aims to Engineer Better Biologics Faster at Lower Cost with Design-in Functionality and Best-in-Class Properties

RECENT SUCCESSES

NEW PHARMA PARTNERSHIPS

- "Astrazeneca Types up \$247m Al-enabled Oncology Antibody Design Pact, Joining Absci's list of Pharma Allies" – Fierce Pharma
- "Skin in the Game: Absci Partners with Almirall on Up-to-\$650M Dermatology Al Collaboration" –GEN News

10 NEW ACTIVE PROGRAMS

Achieved guidance for 2023 with growing partnership momentum for 2024


INTERNAL ASSET PORTFOLIO


 Internal Asset Portfolio focused on cytokine biology
 Lead asset ABS-101, an Al-designed TL1A antibody product candidate


COPYRIGHTE 2024 ABSCI CORPORATION. | ALL RIGHTS RESERVED.


3


absci | 3







































ABS-101 TL1A DATA HIGHLIGHTS

AI Platform Designed ABS-101 Aims for Optimal Therapeutic Profile

ATTRIBUTE	A B S - 101 P R O G R A M *	MERCK (PROMETHEUS) MK-7240	ROCHE (ROIVANT) RVT-3101	S A N O F I (T E V A) T E V - 4 8 5 7 4
Low Immunogenicity**	✓	\checkmark^1	×1.5	-
High Bioavailability	\checkmark	✓1	×1,4	-
Sub-Q autoinjector	\checkmark	×	√ ²	✓ 3
Q8W to once quarterly dosing	\checkmark	1,3	1,3	× ³
		nd low results in ex vivo testing	d exposure with ½-life extension data) reports 41 participants out of DA, and 5 (18%) of these developed	



WELL-POSITIONED TO DELIVER

Absci's talent and Infrastructure for Better Biologics Faster, at Lower Cost

	~160	Unlimiters with deep experience in AI, drug discovery, immunology, and synthetic biology		
	Leading AI team with expertise from:	Image: Notation of the second seco		
	Biologics drug discovery expertise from:	Concentration Cakeda Ca		
	77,000+ Square Feet	State-of-the-art drug creation and wet lab space in Vancouver WA, Absci Al Research (AAIR) lab in NYC, and the Innovation Centre in Zug Switzerland		
	16	Active Programs*		
	3	Named Internal Asset Programs*		
Trademarks, service marks or trade mames referred to harein are the intellectual property of their respective conters. Used this 19 does not imply effiliation, embersement or sponsorbilg of any kind	~\$450M	Capital raised to date		
COPYRIGHTE 2024 ABSCI CORPORATION. ALL RIGHTS RESERVED.	* As of December 31, 2023	absci 20		



